NEW YORK, March 15, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting PhotoMedex Inc (NASDAQ: PHMD), Axiall Corp (NYSE: AXLL), Varian Medical Systems, Inc. (NYSE: VAR), Volcano Corporation (NASDAQ: VOLC) and Navidea Biopharmaceuticals Inc. (NYSE: NAVB). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
PhotoMedex Inc Research Report
PhotoMedex Inc.'s merge with Radiancy has proven to be a great move as the company reaped favorable results in its 2012 Q4. Revenues rose to $54.8 million or a whopping increase of 91%, translating to a gross profit of $43 million. Equipped with a fortified marketing platform and management schemes, the global skin health solutions company is making great leaps ahead of the competition. A huge chunk of the company's success is being attributed to its ability to successfully integrate operations and culture, given that it is operating in different countries of the world. PhotoMedex also introduced several breakthrough products like Neova® and XTRAC®, which gradually won the favor of dermatologists and patients experiencing skin problems such as psoriasis. The Full Research Report on PhotoMedex Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/2c1b_PHMD]
Axiall Corp Research Report
Axiall Corporation, formerly Georgia Gulf Corporation, has just been given a "buy" rating by Citigroup last Tuesday. In fact, many analysts are optimistic that the company will achieve positive results, both in its business and stocks performance. The predictions gave Axiall a challenge to exceed its results during the last quarter. The company reported $0.92 earnings per share for the quarter, beating the analysts' estimate. Consequently, Axiall raked in revenues of $784.70, falling a few dollars short of analysts' estimates. The result was still favorable enough to prompt the company to move towards it goals the current year. On average, analysts and investors are hopeful that Axiall will achieve $5.15/share for fiscal 2013. The Full Research Report on Axiall Corp - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/65e6_AXLL]
Varian Medical Systems, Inc. Research Report
Varian Medical Systems, Inc. further bolstered its rank as one of the world's leading radiotherapy and radiosurgery innovators. The company recently introduced digital X-ray image detectors that are portable, fast, capable of generating high-quality images and usable around the world. This is good news to medical practitioners and patients alike because majority of the said devices require just minimal doses. Varian claimed that the detectors were designed to enable accurate medical decisions while keeping X-ray dose to a minimum. More than just the monetary return when the devices become widely available, Varian is positive that the new technology will yield significant benefits to patients worldwide. The Full Research Report on Varian Medical Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/f40b_VAR]
Volcano Corporation Research Report
Volcano Corporation continues to revolutionize the medical device industry by introducing different types of technologies that make imaging and therapy easier, simpler and a lot less invasive. The company participated in the recent Barclays Global Healthcare Conference 2013 to discuss it recent breakthroughs and new products. Medical device manufacturers and investors attended the said forum, opening Volcano Corporation to more opportunities to share their ideas with likeminded people. The Full Research Volcano Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/6ba1_VOLC]
Navidea Biopharmaceuticals Inc. Research Report
Navidea Biopharmaceuticals, Inc., a biomedical company that develops and sells oncology products, is currently developing four radiopharmaceutical platforms. These include Lymphoseek®, NAV4694, NAV5001 and RIGScan™, which are aimed at identifying the sites and pathways of commonly undetectable disease for improved and more accurate diagnosis, clinical recommendations and patient care. Navidea is also planning to identify and partner with distributors in other markets outside of the US. The Full Research Report on Navidea Biopharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/0b2f_NAVB]
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers
Copyright©2012 PR Newswire.
All rights reserved